Americas GERD & NERD Treatment Market – Overview:
Acid reflux has been a common problem in lifestyle of the average US citizen. The Americas GERD and NERD treatment market is expecting a solid development amid the estimated period. GERD is one of the generally watched gastrointestinal disease over the globe. The pervasiveness of acid reflux and related manifestations has expanded worldwide by about half of the recent decade. Nonetheless, the disease has effects on the wellbeing and nature of patient lives. The significant driving components for the development of the market expanding instances of smoking, changing way of life and unpredictable dietary propensities, expanding rate of indigestion issue (acid reflux). In any case, loss of patent restrictiveness and absence of pipeline medications may moderate the development of the market amid the determined period. The U.S. Census Bureau stated that at least 35% to 40% of the geriatric patients to have at least 1 gastrointestinal symptom in a year. Geriatric population is more prone to develop gastric diseases due to poor immunity and imbalances in the hemostasis of the body.
Premium Sample Report Available @ https://www.marketresearchfuture.com/sample_request/5554 .
As indicated by National Institutes of Health (NIH), it is assessed that 20% of the U.S. population is influenced by GERD and is in charge of 9 million in the U.S. outpatient visit every year. Stomach settling agents are most regularly used to treat GERD and NERD, however there has been watched change in pattern and proton pump inhibitor drugs are utilized to treat GERD and NERD even are accessible in finished the counter. New innovation reports that GERD might be dealt with by stretta methodology in brief time. Stretta treatment is an insignificantly obtrusive system, which helps in lessening GERD indications, enabling the dominant part of patients to wipe out or to a great extent diminish the utilization of PPIs (proton pump inhibitors).
AstraZeneca Plc. (U.K), Addex Pharmaceuticals (Switzerland), Takeda Pharmaceutical (Japan), Eisai Co.,Ltd (Japan), Medigus Ltd. (Israel), RaQualia Pharma Inc. (Japan), Torax Medical(U.S.), Carbon Medical Technologies(U.S.), Endogastric Solutions(U.S.), Medtronic(Ireland), Pfizer(U.S.), Novartis AG. (Switzerland), Glaxo Smith Kline plc. (UK), Valeant Pharmaceuticals (Canada), Ironwood Pharmaceuticals (U.S.) are the key players dominating the Americas GERD & NERD market.
The Americas GERD & NERD treatment market is expecting a healthy growth during the forecasted period. ERD is one of the commonly observed gastrointestinal disorders across the globe. The prevalence of acid reflux and related symptoms has increased worldwide by nearly 50% over the last decade. However, disorder has major effects on the health and quality of patient lives. The major driving factors for the growth of the market increasing cases of smoking, changing lifestyle and irregular dietary habits, increasing incidence of acid reflux disorder (heartburn). However, loss of patent exclusivity and lack of pipeline drugs may slow the growth of the market during the forecasted period.
Americas GERD & NERD Treatment Market – Competitive Analysis:
The market for GERD & NERD treatment is characterized by the presence of several well-established and small players, the global market for GERD & NERD treatment appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The GERD and NERD treatment market is changing continuously during last few decades and is expecting a huge development in coming future. Through extensive research it is found that the market players have adopted the strategy of FDA approvals, agreements and acquisition to expand their market.
The key players involved in this strategy are Pfizer Inc., Valent Pharmaceuticals, Medtronic, Astra Zeneca and Eisai Co.Ltd among others.
For instance, in July 2018, Addex Therapeutics entered into a licensing and collaboration agreement with Indivior PLC for developing and commercializing ADX71441 for the treatment of addiction.
In July 2017, Medigus Ltd. announced that the Chinese exclusive distribution agreement with Shanghai Golden Grand-Medical Instruments Ltd. has expanded for the Medigus Ultrasonic Surgical Endostapler (MUSE) systems in China.
In March 2016, EndoGastric Solutions announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the EsophyX Z device.
Moreover, in July 2015, AstraZeneca announced that it has entered into an agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis.
Get Your Customized Report @ https://www.marketresearchfuture.com/enquiry/5554 .
Major TOC for GERD & NERD Treatment Market:
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 RESEARCH METHODOLOGY
3.1.1 Primary Research Methodology
3.1.2 Data Points Received From The Doctors/ Gastrologist:
3.1.3 Data Points Received From The Manufacturer/ Pharmaceutical Companies:
3.1.4 Data Points Received From Hospitals, Clinics:
3.1.5 Secondary Research Methodology
3.1.6 Market Share Analysis
3.1.7 Trade Analysis
3.1.8 Market Pricing Approach
4 MARKET DYNAMICS
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Cases Of Smoking To Boost The Market Growth (Impact Weightage- 20%)
4.2.2 Rising Cases Of Reflux Disorder During Pregnancy (Impact Weightage- 15%)
4.2.3 Changing Lifestyle And Irregular Dietary Habits (Impact Weightage- 15%)
4.2.4 Increasing Incidence Of Acid Reflux Disorder (Heartburn) Will Boost The American GERD& NERD Treatment Market (Impact Weightage- 25%)
4.2.5 Growing Geriatric Population (Impact Weightage- 15%)
4.2.6 Increasing Demands For Endoscopy Biopsy Procedures For Early Diagnosis (Impact Weightage- 10%)
4.3 Restraints
4.3.1 Loss Of Patent Exclusivity And Lack Of Pipeline Drugs (Impact Weightage- 55%)
4.3.2 High Cost Of The Gastroscopes (Weightage Impact- 45%)
4.4 Opportunity
4.4.1 Development Of New Drugs
4.5 Mega Trends
4.6 Macroeconomic Indicators
4.7 Technology Trends & Assessment
TOC Continued…!
Avail Prime Discount @ https://www.marketresearchfuture.com/check-discount/5554 .
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
